In addition, the authors showed that IRF2 overexpression overcame KRAS-induced resistance mechanisms to anti-PD-1 immunotherapy, and high IRF2 expression in CRC patients could be a predictive marker for anti-PD-1 therapy73. The gene discussed is IRF2; the disease is colorectal carcinoma.